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Abstract
Background: We developed a genetic risk score (GRS) and examined whether the GRS may predict incident stage
3 chronic kidney disease (CKD) independent of common clinical risk factors.
Method: The present study included 2,698 individuals who attended the 15th (1977 to 1979) and the 24th exams
(1995 to 1998) in the Framingham Original cohort or the 6th (1995 to 1998) and the 8th exams (2005 to 2008) in
the Framingham Offspring cohort. A weighted GRS was constructed combining 53 single nucleotide polymorphisms
(SNPs) associated with lower creatinine-based estimated glomerular filtration rate (eGFR). Stage 3 CKD was defined as
eGFR <60 mL/min/1.73 m2, and incident cases were identified at follow-up after excluding prevalent cases at baseline.
Results: A total of 292 incident cases and 2,406 non-cases were identified over, on average, 11 years of follow-up. After
adjustment for sex, age, cohort, baseline eGFR, hypertension, diabetes, and dipstick proteinuria, the odds ratio of incident
stage 3 CKD was 1.37 (95%CI: 1.02–1.83) per 10 alleles of the GRS (P = 0.04). There was no statistically significant difference
between the C-statistic without and with inclusion of the GRS (0.783 and 0.785, respectively; P = 0.39).
Conclusions: A GRS developed based on 53 SNPs associated with reduced eGFR was prospectively associated
with incident stage 3 CKD. However, this score did not substantially improve discrimination of stage 3 CKD beyond the
common clinical risk factors.
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Background
Chronic kidney disease (CKD) contributes to an increas-
ing proportion of public health burden in the US and
other parts of the world [1, 2]. Within the US, the preva-
lence of CKD has steadily increased in the past decades
and 13% of American adults are currently affected by
CKD [3]. The high prevalence of CKD risk factors such
as obesity and type 2 diabetes have contributed to the
growing prevalence of CKD [3, 4]. In addition, CKD is
associated with elevated risk of cardiovascular disease
[5], kidney failure [6], and all-cause mortality [7].
Early detection may help to promote clinical treatment
and potentially slow the progression of CKD [8]. How-
ever, awareness of CKD is relatively low because individ-
uals may experience no symptoms in the early stages of
the disease [9]. Knowledge of common clinical risk
factors such as hypertension and diabetes may facilitate
identification of individuals at-risk of CKD [4]. In
addition to traditional CKD risk factors, there is strong
evidence of genetics influencing CKD risk with heritabil-
ity (h2) estimates of creatinine-based eGFR of 0.33 in the
community-based Framingham Heart Study [10]. Know-
ledge of a patient’s genetic susceptibility to CKD could
potentially enhance the detection of at-risk individuals.
In our prior work, a genetic risk score (GRS), based on
16 single nucleotide polymorphisms (SNPs) previously
identified in association with creatinine-based estimated
glomerular filtration rate (eGFR) [11], did not improve
disease discrimination (C-statistic) for stage 3 CKD
beyond common clinical risk factors [12]. We hypothe-
sized that a potential limitation of our prior work was
the limited number of loci included in the GRS. Fortu-
nately, recent genome-wide association studies have
identified an additional 37 novel loci associated with
eGFR [13]. In this study, we created a GRS from this
list of 53 SNPs associated with creatinine-based eGFR
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(16 known and 37 novel SNPs) and examined
whether, independent of common clinical risk factors,
the updated GRS may predict an increased risk of in-
cident stage 3 CKD in the Framingham Heart Study.
Methods
Study participants
The study sample was derived from the Framingham
Heart Study’s Original and Offspring cohorts, which
have been described previously [14]. The Original cohort
recruited 5,209 participants and the Offspring cohort re-
cruited 5,124 participants when the cohorts were initi-
ated. Participants in the two cohorts were evaluated
approximately every 3 or 4 years. A total of 8,481 partici-
pants had genetic data in the two cohorts. Among these
participants, 600 who attended both the 15th (1977–1979)
and the 24th (1995–1998) exams of the Original cohort
and 2,557 who attended the both the 6th (1995–1998) and
the 8th (2005–2008) exams of the Offspring cohort had
data available for serum creatinine at baseline or follow-
up examinations. We excluded participants who were
missing serum creatinine measurements at either
exam (n = 223) and who had baseline eGFR <60 mL/
min/1.73 m2 (n = 236) for a total of 2,698 participants
in the analytic sample. The Framingham Heart Study
protocols and procedures were approved by the
Institutional Review Board for Human Research at
Boston University Medical Center and all participants
provided written informed consent.
CKD status
Stage 3 CKD was defined based on the updated guide-
line developed by the Kidney Disease Outcomes Quality
Initiative, i.e., eGFR <60 mL/min/1.73 m2 [15, 16].
Briefly, fasting serum creatinine concentration was mea-
sured using either the autoanalyzer technique [17, 18] or
the creatinine imodohydrolase assay [19]. In order to
reduce potential variability between laboratories, serum
creatinine concentration was calibrated using a 2-step
process as previously described [4]. The CKD-EPI
(Chronic Kidney Disease Epidemiology Collaboration)
equation was used to calculate eGFR [20]. Incident stage
3 CKD was defined as new cases identified in the follow-
up exams (the 24th exam in the Original cohort and 8th
exam in the Offspring cohort) among participants free
of stage 3 CKD at baseline (the 15th exam in the Original
cohort and 6th exam in the Offspring cohort).
SNP selection and genotype determination
For the present study, we selected 53 SNPs
(Additional file 1: Table S1) that were associated
with lower creatinine-based eGFR from a consortium
composed of cohorts with European ancestry in the
recent CKDGen genome-wide association study [13].
Genotyping was performed with Affymetrix 500 K
mapping array and the Affymetrix 50 K supplemen-
tal array. Replicated quality control samples yielded
high concordance (>99%), with the overall call rate
>95%. All variants were imputed to 1000G phase 1
version 3 (2012) using MACH. Genotypes were repre-
sented as continuous dosages from 0 to 2. A weighted
GRS was developed by summing together the product
of the number of risk alleles (eGFR lowering alleles)
and the corresponding regression coefficient derived
from the CKDGen meta-analysis [13]. For a more in-
tuitive unit of interpretation, the GRS was divided by
the sum of regression coefficients (∑i = 1
S3 b = 0.399) and
multiplied by the total number of loci (N = 53).
Therefore, one point of the GRS approximately repre-
sented one risk allele and a greater GRS represents
higher genetic susceptibility to low eGFR.
Covariates assessment
At each visit, cardiovascular disease risk factors were
measured by following standard protocols [21]. Systolic
blood pressure (SBP) and diastolic blood pressure (DBP)
were measured twice by same physician, and the average
of the two measurements was used. Hypertension was
defined as SBP ≥140 mmHg, DBP ≥90 mmHg, or use of
anti-hypertensive medication. Type 2 diabetes was de-
fined as fasting plasma glucose ≥126 mg/dl or use of
anti-hyperglycemic treatment. A urine dipstick test on a
spot urine sample was used to measure proteinuria [22],
which was defined when a trace protein or higher was
detected.
Statistical analysis
Participant characteristics were presented as mean ±
standard deviation for continuous variables and propor-
tion and counts for dichotomous variables. The pro-
spective association of the GRS and incident stage 3
CKD was analyzed using multiple logistic regression
models with generalized estimating equations. The re-
latedness in our study sample was accounted for using
generalized estimating equations. Odds ratio (OR) of in-
cident stage 3 CKD was presented based on increment
of 10 alleles of the GRS. Two models were considered:
model 1 was adjusted for age, sex, and an indicator of
cohort status (Original or Offspring cohort), and model
2 was adjusted for model 1 covariates and CKD risk
factors including baseline eGFR, hypertension, type 2
diabetes, and proteinuria. To assess the discrimination
capability of the GRS, we performed receiver-operating
characteristic curve (ROC) analysis and used a non-
parametric model to compare the area under the curve
(AUC or the C-statistic) between the fully adjusted
model with and without the GRS [23].
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In a secondary analysis, we performed the GRS and in-
cident stage 3 CKD analysis stratified by age (<60 and
≥60 years) to assess if the prediction of the GRS is im-
proved among younger as compared to older partici-
pants. Additionally, a GRS-by-age (<60 and ≥60 years)
interaction term was added to the regression model to
assess any potential effect modification. We also catego-
rized GRS into quartiles to investigate the possibility of a
threshold effect that may affect the score’s discrimin-
ation capability.
All statistical analyses were conducted using R (ver-
sion 2.13.0; R Foundation) and SAS statistical soft-
ware (version 9.3; SAS Institute). A two-tailed P < 0.05
was considered statistically significant, unless other-
wise specified.
Results
Baseline characteristics of the 2,698 participants are pre-
sented in Table 1. The mean follow-up period was
11 years. We identified 292 incident stage 3 CKD cases
(10.8%) at the follow-up period. The distribution of GRS
among incident stage 3 CKD cases and non-cases is shown
in Fig. 1. The GRS was slightly higher in incident stage 3
CKD cases compared with non-cases, i.e., those with stage
3 CKD were slightly more genetically predisposed to lower
eGFR. The mean GRS was 56.2 ± 4.6 in stage 3 CKD cases
and 55.7 ± 4.4 in non-cases (Pdifference = 0.06).
As shown in Table 2, after adjustment for age, sex, and
cohort, the odds ratio (OR) of incident stage 3 CKD was
1.44 (95%CI: 1.08, 1.93) per 10 alleles of the GRS, i.e., an
average of 44% increase in risk of incident stage 3 CKD,
P = 0.01. Additional adjustment for baseline clinical
CKD risk factors did not substantially attenuate the
association between the GRS and incident stage 3 CKD
(OR = 1.37, 95%CI: 1.02, 1.83, P = 0.04). While the up-
dated GRS did show improved prediction for incident
CKD independent of traditional risk factors, we did not
observe improved discrimination of the updated GRS in
ROC analysis (Fig. 2). In sex-, age-, and cohort-adjusted
model, the C-statistic was 0.753, which was increased to
0.783 after additional consideration of baseline eGFR,
hypertension, diabetes, and proteinuria, Pdifference <
0.001. The C-statistic was mostly unchanged in the fully
adjusted model without the GRS and with the GRS,
0.783 vs. 0.785, Pdifference = 0.39.
In secondary analyses, ORs of incident stage 3 CKD
using GRS quartiles are presented in Fig. 3. In model 1
(sex- and age-adjusted model), participants in the high-
est quartile of GRS were at 47% (OR = 1.47, 95% CI:
1.03, 2.12) greater risk of stage 3 CKD compared to
those in the lowest quartile of GRS, P = 0.04. After add-
itional adjustment for clinical risk factors, OR of inci-
dent stage 3 CKD in the top GRS quartile category was
1.39 (95%CI: 0.96, 2.02, P = 0.08) compared with the
lowest GRS quartile category.
To assess the potential improvement in GRS predic-
tion among the younger age group, we compared the as-
sociation of the GRS with incident CKD between
participants <60 and ≥60 years old. There were 82 inci-
dent stage 3 CKD cases and 1,585 non-cases among
younger participants, and 210 incident cases and 821
Table 1 Baseline characteristics of participants
N = 2,698
Genetic risk score (106 alleles) 55.8 ± 4.0
Age, years 57.6 ± 8.6
Women, % (n) 54.1 (1459)
BMI, kg/m2 27.5 ± 4.9
eGFR, mL/min/1.73 m2 92.3 ± 24.3
Hypertension, % (n) 35.2 (948)
Type 2 diabetes, % (n) 6.6 (179)
Dipstick proteinuria, % (n) 15.8 (424)
Mean ± standard deviation or proportion (counts)
eGFR estimated glomerular filtration rate
Fig. 1 Genetic risk score (53 SNPs) distribution in participants with
and without stage 3 chronic kidney disease (CKD). Sample size was
292 for stage 3 CKD cases and 2406 for non-stage 3 CKD cases
Table 2 Odds ratio (OR) of stage 3 CKD
Effect size of the genotype score
Odds Ratio (95% CI)
P-value
Model 1 1.44 (95% CI: 1.08, 1.93) 0.01
Model 2 1.37 (95% CI: 1.02, 1.83) 0.04
Odds ratio and 95% CI were calculated based on increase of per 10 alleles of
genetic risk score
Model 1 was adjusted for age, sex, and Framingham cohort
Model 2 was adjusted for age, sex, Framingham cohort, baseline estimated
glomerular filtration rate, hypertension, diabetes, and proteinuria
GRS genetic risk score
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non-cases among older participants. No significant inter-
action was observed between the GRS and age, P-inter-
action = 0.89. The ORs of stage 3 CKD in both age
groups were similar as that observed in entire study
sample, OR = 1.29 (95%CI: 0.75, 2.21, P = 0.4) in younger
participants and OR = 1.38 (95%CI: 0.96, 1.98, P = 0.08)
in older participants.
Discussion
An updated genetic risk score using 53 genetic loci asso-
ciated with reduced kidney function predicted incident
stage 3 CKD in a cohort of middle-aged and older adults
with a mean of 11 years of follow-up. Each increment of
10 alleles was associated with a 37% increased risk of
CKD adjusted for age, sex and common clinical risk fac-
tors. Despite this, the updated GRS did not substantially
improve the discrimination of CKD beyond the known
clinical risk factors.
In our prior work, we showed that developing a GRS
based on 16 genetic loci that were associated with
reduced kidney function was not associated with inci-
dent CKD after adjustment for clinical risk factors [12].
The present study updated the GRS by adding 37 newly
identified genetic loci. We demonstrated that this new
GRS constructed from a more comprehensive set of gen-
etic markers was associated with incident CKD after
consideration of common clinical risk factors. However,
as we have demonstrated before [12], the GRS remained
a poor tool for discrimination of incident CKD beyond
common clinical risk factors. Similar findings have been
observed in many other studies for different phenotypes
[24, 25]. In an earlier study, a GRS was constructed
using 18 SNPs associated with type 2 diabetes available
at that time to predict incident type 2 diabetes cases
[26]. However, this study showed the GRS did not much
improve the C-statistic beyond simple clinical risk fac-
tors. In later studies, more SNPs were included to up-
date the prior GRSs [24, 27, 28], with the latest GRS was
composed of 65 type 2 diabetes associated SNPs [28].
However, in all of these later studies, the increase in dis-
crimination was marginal after combining the GRS with
common clinical risk factors [24, 27, 28]. Therefore, As
suggested by us [12] and many others [24, 27, 28], GRSs
developed using common genetic variants that nomin-
ally contribute to phenotypic variation may not improve
disease discrimination beyond common clinical risk
factors alone.
Despite the consistency between our observations and
many other studies, the discriminatory power of the
newly constructed GRS in the present study may be lim-
ited by several aspects. The 37 newly discovered loci
have relatively small effect sizes, and the 53 SNPs only
explain a small proportion of the variability (3.2%) in
eGFR (13). The GRS developed in the present study uti-
lized common genetic variants, i.e., 53 SNPs with minor
allele frequency of 0.05 or greater. It is possible that less
common or rare SNPs may be discovered from sequen-
cing technologies, and these rare SNPs may represent
greater variability in eGFR [29, 30]. However, since they
will be rarer, the impact of low frequency variants on
overall disease variation in the general population may
be similarly low. Incorporating markers from emerging
(1) Age, sex, & FHS cohort (C-statistic=0.753)
(2) Age, sex, FHS cohort, & clinical factors (C-statistic=0.783)
(3) Age, sex, FHS cohort, clinical factors, & GRS (C-statistic=0.785)







Fig. 2 Receiver-operating characteristic curves for stage 3 chronic
kidney disease. The C-statistics are based on logistic regression models
with adjustment for age, sex, Framingham cohort, and clinical risk factors
including baseline estimated glomerular filtration rate, hypertension, type















Q1 (Ref.) Q2 Q3 Q4
GRS Quartile Categories
Model 1: Q2 vs. Q1: OR=1.18 (95%CI: 0.82, 1.72), P-value=0.38
Q3 vs. Q1: OR=1.15 (95%CI: 0.79, 1.68), P-value=0.47
Q4 vs. Q1: OR=1.47 (95%CI: 1.03, 2.12), P-value=0.04
Model 2: Q2 vs. Q1: OR=1.18 (95%CI: 0.81, 1.73), P-value=0.39
Q3 vs. Q1: OR=1.10 (95%CI: 0.75, 1.61), P-value=0.64
Q4 vs. Q1: OR=1.39 (95%CI: 0.96, 2.02), P-value=0.08
Fig. 3 The association of quartile GRS and incident CKD. The GRS
ranged from 40.6 to 52.7, 52.8 to 55.8, 55.8 to 58.7, and 55.8 to 71.4
from the lowest to the highest quartile category, respectively. Model
1 was adjusted for age, sex, and Framingham cohort. Model 2 was
adjusted for age, sex, Framingham cohort, and clinical risk factors
including baseline estimated glomerular filtration rate, hypertension, type
2 diabetes, and dipstick proteinuria. OR: odds ratio; GRS: genetic risk
score; CKD: chronic kidney disease. Y axis is in natural logarithmic scale
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fields such as epigenomics, transcriptomics, or metabo-
lomics may help to develop a multi-disciplinary “omics”
risk score that may have sufficient discriminatory power
for complex diseases such as CKD. Further investigation
into the genetic architecture of renal function and dis-
ease may lead to development of a GRS with improved
discriminatory capacity.
The present study suggests that common clinical risk
factors rather than genetic markers are more useful in
disease prediction with our current knowledge. However,
we have demonstrated that the GRS is a strong risk fac-
tor for stage 3 CKD, independent of clinical risk factors.
Additionally, continuing research into the genetic archi-
tecture of renal function would provide additional
insight into the pathophysiological pathways underlying
the development of CKD.
The present data utilized comprehensive clinical data
collected from the Framingham Heart Study Original
and Offspring cohorts. We were able to examine stage 3
CKD status across 11 years, on average, of follow-up.
Some limitations regarding the genetic risk score have
been discussed above, e.g., SNPs included in the GRS
only accounted for a modest proportion of eGFR herit-
ability. More genetic markers may be discovered in the
future, and incorporation of these markers such as rare
genetic variants influencing risk of stage 3 CKD may im-
prove the discriminatory ability of the GRS. In addition,
our study participants are primarily of European ances-
try and therefore the GRS may not be generalizable to
other ancestral populations with different allele frequen-
cies and linkage disequilibrium structure.
Conclusions
Our findings demonstrate that a GRS constructed based
on 53 risk alleles for reduced kidney function was associ-
ated with incident cases of stage 3 CKD in our adult
study sample, however, did not substantially improve
disease discrimination beyond clinical risk factors alone.
These results emphasize early identification of adverse
clinical risk factors should remain a priority for risk pre-
diction in kidney disease.
Additional file
Additional file 1: Characteristics of SNPs included in the genetic risk
score. The supplemental table provides characteristics of the 53 SNPs
included in the genetic risk score. (DOC 79 kb)
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